Suchergebnis | Hamburg Open Science

Facetten

24 Einträge gefunden

Cortisol, DHEA and DHEA-S during exposure therapy in patients with obsessive-compulsive disorder – secretion patterns and prediction of treatment response
2020 - Forschungsinformationssystem des UKE - frei zugänglich
Impact of physical or sexual childhood abuse on plasma DHEA, DHEA-S and cortisol in a low-dose dexamethasone suppression test and on cardiovascular risk parameters in adult patients with major depression or anxiety disorders
2018 - Forschungsinformationssystem des UKE
Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic-pituitary-adrenal axis and sleep in healthy men.
2010 - Forschungsinformationssystem des UKE
Decreased recognition of negative affect after selective serotonin reuptake inhibition is dependent on genotype.
2010 - Forschungsinformationssystem des UKE
CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks.
2010 - Forschungsinformationssystem des UKE
Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.
2009 - Forschungsinformationssystem des UKE
Increased DHEA and DHEA-S plasma levels in patients with post-traumatic stress disorder and a history of childhood abuse.
2009 - Forschungsinformationssystem des UKE
The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype.
2009 - Forschungsinformationssystem des UKE
Does 5-HTTLPR genotype influence willingness to participate in panic challenges?
2009 - Forschungsinformationssystem des UKE
No effect of six weeks of treatment with escitalopram on mood in healthy volunteers--irrespective of genotype for the promoter of the serotonin transporter.
2008 - Forschungsinformationssystem des UKE
A combined dexamethasone/corticotropin-releasing hormone test in patients with chronic PTSD--first preliminary results.
2008 - Forschungsinformationssystem des UKE
Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition.
2007 - Forschungsinformationssystem des UKE
Mineralocorticoid receptor function in posttraumatic stress disorder after pretreatment with metyrapone.
2006 - Forschungsinformationssystem des UKE
Metyrapone tests in patients with panic disorder.
2004 - Forschungsinformationssystem des UKE
Valproate monotherapy in the treatment of civilian patients with non-combat-related posttraumatic stress disorder: an open-label study.
2004 - Forschungsinformationssystem des UKE
Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
2004 - Forschungsinformationssystem des UKE
Overnight metyrapone and combined dexamethasone/metyrapone tests in post-traumatic stress disorder: preliminary findings.
2004 - Forschungsinformationssystem des UKE
Endocrine and cardiovascular responses to corticotropin-releasing hormone in patients with posttraumatic stress disorder: a role for atrial natriuretic peptide?
2003 - Forschungsinformationssystem des UKE
Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans.
2003 - Forschungsinformationssystem des UKE
The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone.
2003 - Forschungsinformationssystem des UKE

Aktive Facetten

Facetten

Zugriff

Einrichtung

Medientyp

Karte

Erscheinungsjahr

Autor/in

Sprache

Cortisol, DHEA and DHEA-S during exposure therapy in patients with obsessive-compulsive disorder – secretion patterns and prediction of treatment response

Impact of physical or sexual childhood abuse on plasma DHEA, DHEA-S and cortisol in a low-dose dexamethasone suppression test and on cardiovascular risk parameters in adult patients with major depression or anxiety disorders

Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic-pituitary-adrenal axis and sleep in healthy men.

Decreased recognition of negative affect after selective serotonin reuptake inhibition is dependent on genotype.

CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks.

Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.

Increased DHEA and DHEA-S plasma levels in patients with post-traumatic stress disorder and a history of childhood abuse.

The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype.

Does 5-HTTLPR genotype influence willingness to participate in panic challenges?

No effect of six weeks of treatment with escitalopram on mood in healthy volunteers--irrespective of genotype for the promoter of the serotonin transporter.

A combined dexamethasone/corticotropin-releasing hormone test in patients with chronic PTSD--first preliminary results.

Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition.

Mineralocorticoid receptor function in posttraumatic stress disorder after pretreatment with metyrapone.

Metyrapone tests in patients with panic disorder.

Valproate monotherapy in the treatment of civilian patients with non-combat-related posttraumatic stress disorder: an open-label study.

Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.

Overnight metyrapone and combined dexamethasone/metyrapone tests in post-traumatic stress disorder: preliminary findings.

Endocrine and cardiovascular responses to corticotropin-releasing hormone in patients with posttraumatic stress disorder: a role for atrial natriuretic peptide?

Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans.

The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone.